The U.S. Food and Drug Administration (FDA) has approved GSK’s respiratory syncytial virus (RSV) vaccine for adults aged 50 and older who are at higher risk of severe RSV. This makes it the first RSV vaccine authorized for this age group. Previously, the vaccine was only approved for adults 60 and older. Clinical Trials and … Read more